Cagrilintide (also known as Cagri, AM833) is a long-acting amylin analog studied for appetite and weight, often with semaglutide. This page covers what the published research does — and does not — establish about it in relation to fat loss and weight management.
Cagrilintide is researched for Appetite regulation, Weight management — which is why it appears in discussions of fat loss and weight management.
Research status: Clinical trials — investigational.
How Cagrilintide is thought to work
Cagrilintide is a long-acting analog of amylin, a hormone co-released with insulin that promotes satiety and slows gastric emptying. It is studied on its own and combined with semaglutide (as CagriSema) for appetite and weight management.
What it does not establish
Investigational and not approved as a standalone product. Medical supervision advised.
Nothing on this page is a recommendation to use Cagrilintide, and Selpho publishes no dosing, reconstitution or sourcing information. Read how we decide what goes in the library.
Commonly researched alongside
A GLP-1 receptor agonist approved for type 2 diabetes and weight management.
Other peptides researched for Fat Loss
A GLP-1 receptor agonist approved for type 2 diabetes and weight management.
A dual GIP/GLP-1 receptor agonist approved for diabetes and weight management.
An investigational triple GIP/GLP-1/glucagon agonist studied for weight loss.
An investigational GLP-1/glucagon dual agonist studied for weight and liver health.
Frequently asked questions
Clinical trials — investigational. Research relevant to this area covers appetite regulation, weight management. That is a description of where the research points, not evidence that it will work for you — and Selpho does not provide dosing or medical advice.
Clinical trials — investigational.
Investigational and not approved as a standalone product. Medical supervision advised. Always speak to a licensed healthcare professional before considering any peptide.
Appetite regulation and weight management, both alone and in combination with semaglutide. It is investigational.
Amylin is a hormone released with insulin that promotes fullness; a long-acting analog like cagrilintide extends that satiety effect.
Is Cagrilintide right for your situation?
Describe your goals and the free Peptide Advisor will match them against the research — no signup, no sales pitch.
Ask the Advisor — freeThis page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.